Study to Assess the Effects and Safety of ZGN-1061 in Overweight and Obese Participants With Type 2 Diabetes

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 188 participants.

Also called NCT03254368

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 188 participants (enrolled count) (from the registry)
Sponsor
Zafgen, Inc. (from the registry)
Registry
  • NCT NCT03254368
  • WHO UTN U1111-1196-7527
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Australia, New Zealand (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03254368. Randomized; quadruple masking; primary purpose treatment. Start 2017-09-12 (actual); primary completion 2018-11-12 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Assess the Effects and Safety of ZGN-1061 in Overweight and Obese Participants With Type 2 Diabetes
Condition
Type 2 Diabetes Mellitus
Condition
Overweight and Obesity
Intervention (Drug)
ZGN-1061
Intervention (Drug)
Placebo
Lead sponsor
Zafgen, Inc. (class: industry)

Record details

Record id
cardio:ct-nct03254368
Content hash
25ecfd10b61a2a0438447b5008464ae84dcd41f2b129deea74203b43f3f76762